Publicaciones en las que colabora con Josep Tabernero Caturla (20)

2023

  1. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

2022

  1. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800

2017

  1. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

    Annals of Oncology, Vol. 28, Núm. 12, pp. 2932-2942

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2015

  1. A Phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

    Clinical Cancer Research, Vol. 21, Núm. 4, pp. 730-738

2014

  1. Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

    European Journal of Cancer, Vol. 50, Núm. 3, pp. 496-505

2013

  1. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

    Cancer Discovery, Vol. 3, Núm. 4, pp. 406-417

  2. Phase i study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors

    Cancer Chemotherapy and Pharmacology, Vol. 72, Núm. 1, pp. 75-83

2012

  1. First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

    British Journal of Cancer, Vol. 106, Núm. 8, pp. 1379-1385

2011

  1. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor,,in patients with advanced solid tumors

    Journal of Clinical Oncology, Vol. 29, Núm. 28, pp. 3783-3790

2010

  1. Treatment of cancer with oral drugs: A position statement by the Spanish Society of Medical Oncology (SEOM)

    Annals of Oncology

2009

  1. Phase II randomized study of plitidepsin (aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma

    Marine Drugs, Vol. 7, Núm. 1, pp. 57-70

2008

  1. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors

    Clinical Cancer Research, Vol. 14, Núm. 4, pp. 1116-1123

  2. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer

    Clinical Cancer Research, Vol. 14, Núm. 1, pp. 215-223

2007

  1. Phase II study of trabectedin in pretreated patients with advanced colorectal cancer

    Clinical Colorectal Cancer, Vol. 6, Núm. 7, pp. 522-528

2004

  1. Incidence of contralateral germ cell testicular tumors in south Europe: Report of the experience at 2 Spanish university hospitals and review of the literature

    Journal of Urology, Vol. 171, Núm. 1, pp. 164-167

2003

  1. Review of a promising new agent - Pemetrexed disodium

    Cancer

2000

  1. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer

    European Journal of Cancer, Vol. 36, Núm. SUPPL. 2, pp. 17-25

  2. Tumor markers at the time of recurrence in patients with germ cell tumors

    Cancer, Vol. 88, Núm. 1, pp. 162-168

1997

  1. Mediastinal non-seminomatous germ cell turnouts (MNSGCT) treated with cisplatin-based combination chemotherapy

    Annals of Oncology, Vol. 8, Núm. 6, pp. 555-559